Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × rocakinogene sifuplasmid × Genitourinary × Clear all
NCT03502785 2025-07-10

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Inovio Pharmaceuticals

Phase 1/2 Completed
35 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT02514213 2017-12-26

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Inovio Pharmaceuticals

Phase 1 Completed
62 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡